Therapeutic strategies in pulmonary hypertension of the newborn: Where are we now?

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4640-4653

  Luna, Manuel Sanchez ^a   Franco, Ma Luisa ^a   Bernardo, Belén ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

ECMO; HFOV; iNO; Newborn; PPHN; Sildenafil

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; CYCLIC AMP; CYCLIC GMP; LUNG SURFACTANT; MAGNESIUM SULFATE; MILRINONE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; RHO KINASE; SILDENAFIL; VASODILATOR AGENT; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ALTERNATIVE MEDICINE; ARTICLE; ARTIFICIAL VENTILATION; CONGENITAL DIAPHRAGM HERNIA; EXTRACORPOREAL OXYGENATION; FETUS CIRCULATION; HUMAN; HYPOTENSION; HYPOXEMIA; LUNG CIRCULATION; MECONIUM ASPIRATION; NEWBORN; NEWBORN SEPSIS; NONHUMAN; PERSISTENT PULMONARY HYPERTENSION; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; PATHOLOGY; REVIEW; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; NITRIC OXIDE; PIPERAZINES; PURINES; RESPIRATION, ARTIFICIAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SULFONES;

EID: 84875245328     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306475     Document Type: Article

References (176)

1. Gersony WM. Neonatal pulmonary hypertension: pathophysiology, classification and etiology. Clin Perinatol 1984; 11: 517-524.
2. Kinsella JP and Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995;126: 853-864,.
3. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, and Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976;89: 626-630,.
4. Murphy JD, Rabinovitch M, Goldstein JD, and Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 1981;98: 962-967.
5. Dukarm RC, Steinhorn RH, Morin FC. The normal pulmonary vascular transition at birth. Clin Perinatol 1996; 23: 711-26
6. Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol 1999;26:601-619.
7. Abman SH, Shanley PF, Accurso FJ. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83: 1849-1858, 1989.
8. Belik J, Keeley FW, Baldwin F, Rabinovitch M. Pulmonary hypertension and vascular remodeling in fetal sheep. Am J Physiol 266: H2303-2309, 1994.
9. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289: L798-806.
10. Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endotheliumderived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 259: H1921-1927, 1990.
11. Basu S, Datta BN, Khandelwal N. Morphologic changes in pulmonary vasculature with arteriographic correlation. Angiology 1996;47:375-380.
12. Allen K, Haworth SG. Human postnatal pulmonary arterial remodeling. Ultrastructural studies of smooth muscle cell and connective tissue maturation. Lab Invest 1988;59:702-709.
13. Ziegler JW, Ivy DD, Kinsella JP, Abmans SH. The role of nitric oxide, endothelin and prostaglandins in the transition of the pulmonary circulation. Clin Perinatol 1995; 22: 387-403.
14. Sud N, Black SM. Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression. DNA Cell Biol 2009; 28: 543-53.
15. Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr 2009; 98: 1683-5.
16. Goissen C, Ghyselen L, Tourneux P, Krim G, Storme L, Bou P, Maingourd Y. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr 2008; 167: 437-40.
17. Fineman JR, Wong J, Morin FC III, Wild LM, Soifer SJ. Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs. J Clin Invest 1994;93:2675-83.
18. Nelin LD, Moshin J, Thomas CJ, Sasidharan P, Dawson CA. The effect of inhaled nitric oxide on the pulmonary circulation of the neonatal pig. Pediatr Res 1994;35:20-4.
19. Lipsitz EC, Weinstein S, Smerling AJ, Stolar CJH. Endogenous nitric oxide and pulmonary vascular tone in the neonate. J Pediatr Surg 1996;31:137-40.
20. Parker TA, le Cras TD, Kinsella JP, Abman SH. Developmental changes in endothelial nitric oxide synthase expression and activity in ovine fetal lung. Am J Physiol Lung Cell Mol Physiol. 2000;278:L202-L208.
21. Bloch KD, Filippov G, Sanchez LS, Nakane M, de la Monte SM. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol Lung Cell Mol Physiol. 1997;272:L400-L406.
22. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML. Neonatal pulmonary hypertension-urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001; 344: 1832-8.
23. Farrow K, Fliman P, Steinhorn R. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005;29:8-14.
24. Hageman J, Adams M, Gardner T. Persistent pulmonary hypertension of the newborn: trends in incidence, diagnosis, and management. Am J Dis Child. 1984;138:592-595
25. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Oh W, Ehrenkranz RA, Fanaroff AA. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105: 14-20
26. Geggel RL, Reid LM. The structural basis of PPHN. Clin Perinatol 1984; 11: 525-49.
27. Hopkins N, McLoughlin P. The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat 201: 335-348, 2002.
28. Walsh-Sukys M. Persistent pulmonary hypertension of the newborn. The black box revisited. Clin Perinatol. 1993;20: 127-143
29. Abman S. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension of the newborn. Pediatr Pulmonol Suppl. 1999;18:201-204.
30. Bishop NB, Stankiewicz P, Steinhorn RH. Alveolar Capillary Dysplasia. Am J Respir Crit Care Med 2011.
31. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Paediatr Pulmonol Suppl. 2005;39:492-503.
32. Farrow K, Fliman P, Steinhorn R. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005;29:8-14.
33. Durmowicz AG, Orton EC, Stenmark KR. Progressive loss of vasodilator responsive component of pulmonary hypertension in neonatal calves exposed to 4,570 m. Am J Physiol 1993;265:2175-2183.
34. Fike CD, Kaplowitz MR. Effect of chronic hypoxia on pulmonary vascular pressures in isolated lungs of newborn pigs.J Appl Physiol 1994;77:2853-2862.
35. Haworth SG, Hislop AA. Effect of hypoxia on adaptation of the pulmonary circulation to extra-uterine life in the pig. Cardiovasc Res 1982;16:293-303.
36. Hall SM, Gorenflo M, Reader J, Lawson D, Haworth SG. Neonatal pulmonary hypertension prevents reorganisation of the pulmonary arterial smooth muscle cytoskeleton after birth. J Anat 2000;196:391-403.
37. Stenmark KR, Aldashev AA, Orton EC, Durmowicz AG, Badesch DB, Parks WC, Mecham RP, Voelkel NF, Reeves JT. Cellular adaptation during chronic neonatal hypoxic pulmonary hypertension. Am J Physiol [Suppl] 1991;261:97-104.
38. Belik J, Halayko AJ, Rao K, Stephens NL. Fetal ductus arteriosus ligation. Pulmonary vascular smooth muscle biochemical and mechanical changes. Circ Res 1993;72:588-596.
39. Davey AM, Becker JD, Davis JM. Meconium aspiration syndrome: physiological and inflammatory changes in a newborn piglet model. Pediatr Pulmonol 1993;16:101-108.
40. Runkle B, Goldberg RN, Streitfeld MM, Clark MR, Buron E, Setzer ES, Bancalari E. Cardiovascular changes in group B streptococcal sepsis in the piglet: response to indomethacin and relationship to prostacyclin and thromboxane A2. Pediatr Res 1984;18:874-8.
41. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005; 39: 492-503.
42. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120: e272-82.
43. Nakwan N, Nakwan N, Wannaro J. Predicting mortality in infants with persistent pulmonary hypertension of the newborn with the Score for Neonatal Acute Physiology-Version II (SNAP-II) in Thai neonates. J Perinat Med 2011.
44. Noponen T, Nordh A, Berg A, Ley D, Hansson SR, Pesonen E, Fellman V. Circulatory effects of inhaled iloprost in the newborn preterm lamb. Pediatr Res 2009; 66: 416-22.
45. Urlesberger B, Grossauer K, Pocivalnik M, Avian A, Müller W, Pichler G. Regional oxygen saturation of the brain and peripheral tissue during birth transition of term infants. J Pediatr 2010; 157: 740-4.
46. Soleymani S, Borzage M, Seri I. Hemodynamic monitoring in neonates: advances and challenges. J Perinatol 2010; 30: S38-45.
47. Weindling AM. Peripheral oxygenation and management in the perinatal period. Semin Fetal Neonatal Med 2010; 15: 208-15.
48. McSwain SD, Hamel DS, Smith PB, Gentile MA, Srinivasan S, Meliones JN, Cheifetz IM. End-tidal and arterial carbon dioxide measurements correlate across all levels of physiologic dead space. Respir Care 2010; 55: 288-93.
49. Hoffman GM, Nelin LD. Mean airway pressure and response to inhaled nitric oxide in neonatal and pediatric patients. Lung 2005; 183: 441-53.
50. Arnold JH, Bower LK, Thompson JE. Respiratory deadspace measurements in neonates with congenital diaphragmatic hernia. Crit Care Med 1995; 23: 371-5.
51. Joynt C, Bigam DL, Charrois G, Jewell LD, Korbutt G, Cheung PY. Milrinone, dobutamine or epinephrine use in asphyxiated newborn pigs resuscitated with 100% oxygen. Intensive Care Med 2010; 36: 1058-66.
52. Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2010; [11]: CD007802.
53. Deb B, Bradford K, Pearl RG. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28: 795-799.
54. Santhosh KT, Elkhateeb O, Nolette N, Outbih O, Halayko AJ, Dakshinamurti S. Milrinone attenuates thromboxane receptor-mediated hyper-responsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol 2011.
55. McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006; 21: 217-22.
56. Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar VH, Russell JA, Steinhorn RH. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2009; 10: 106-12.
57. Nielsen J, Nilsson M, Fredén F, Hultman J, Alström U, Kjaergaard J, Hedenstierna G, Larsson A. Central hemodynamics during lung recruitment maneuvers at hypovolemia, normovolemia and hypervolemia. A study by echocardiography and continuous pulmonary artery flow measurements in lung-injured pigs. Intensive Care Med 2006; 32: 585-94.
58. van Kaam AH, Rimensberger PC. Lung-protective ventilation strategies in neonatology: what do we know-what do we need to know? Crit Care Med 2007; 35: 925-931.
59. Dambrosio M, Roupie E, Mollett JJ, et al. Effects of positive endexpiratory pressure and different tidal volumes on alveolar recruitment and hyperinflation. Anesthesiology 1997;87:495-503.
60. Bhutani VK. Developing a systems approach to prevent meconium aspiration syndrome: lessons learned from multinational studies. J Perinatol 2008; 28: S30-5.
61. Keszler M. State of the art in conventional mechanical ventilation. J Perinatol 2009; 29: 262-75.
62. Wheeler K, Klingenberg C, McCallion N, Morley CJ, Davis PG. Volumetargeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2010; (11): CD003666.
63. de Jaegere A, van Veenendaal MB, Michiels A, van Kaam AH. Lung recruitment using oxygenation during open-lung high-frequency ventilation in preterm infants. Am J Respir Crit Care Med 2006;174:639-45.
64. Kinsella JP, Abman SH: Clinical approach to inhaled NO therapy in the newborn. J Pediatr 2000; 136:717-726.
65. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, Redding GJ, deLemos RA, Sardesai S, McCurnin DC, Moreland SG, Cutter GR, Abman SH.: Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131:55-62.
66. Kinsella JP, Abman SH. High-frequency oscillatory ventilation augments the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn: Nitric Oxide Study Group. Chest 1998;114:100S.
67. Mercier JC, Lacaze T, Storme L, Roze JC, Dinh-Xuan AT, Dehan M. Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure. French Paediatric Study Group of Inhaled NO. Eur J Pediatr 1998;157:747-752.
68. Hoehn T, Krause M, Hentschel R. High-frequency ventilation augments the effect of inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Eur Respir J 1998;11: 234-238.
69. Velaphi S, Van Kwawegen A. Meconium aspiration syndrome requiring assisted ventilation: perspective in a setting with limited resources. J Perinatol 2008; 28: S36-42.
70. Findlay RD, Taeusch W, Walther FJ: Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97:48-52.
71. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A. A randomized trial of early versus standard inhaled nitric oxide therapy in term and nearterm newborn infants with hypoxic respiratory failure. Pediatrics 2004; 113: 559-64.
72. Drummond WH, Gregory GA, Heymann MA, Phibbs RA. The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension. J Pediatr 1981; 98: 603-611.
73. Peckham G, Fox WW. Physiologic factors affecting pulmonary artery pressure in infants with persistent pulmonary hypertension. J Pediatr 1978; 93: 1005-1010
74. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Oh W, Ehrenkranz RA, Fanaroff AA. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 14-20.
75. Kusuda S, Shishida N, Miyagi N, Hirabayashi M, Kim TJ. Cerebral blood flow during treatment for pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 1999; 80: F30-3.
76. Zhou W, Liu W. Hypercapnia and hypocapnia in neonates. World J Pediatr 2008; 4:192-6.
77. Walsh Sukys MC, Cornell DJ, Houston LN, Keszler M, Kanto WP Jr. Treatment of persistent pulmonary hypertension of the newborn without hyperventilation: an assessment of diffusion of innovation. Pediatrics 1994;94: 303-6.
78. Gupta A, Rastogi S, Sahni R, Bhutada A, Bateman D, Rastogi D, Smerling A, Wung JT. Inhaled nitric oxide and gentle ventilation in the treatment of pulmonary hypertension of the newborn a single-center, 5-year experience. J Perinatol 2002; 22: 435-41.
79. Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev 2005; 6: 111-6.
80. Lyrene RK, Welch KA, Godoy G, Philips JB III. Alkalosis attenuates hypoxic pulmonary vasoconstriction in neonatal lambs. Pediatr Res 1985; 19: 1268-1271.
81. Schreiber MD, Heymann MA, Soifer SJ. Increased arterial pH, not decreased PaCO2, attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr Res 1986; 20: 113-117.
82. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 818-9
83. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; (4): CD000399.
84. Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in severe hypoxaemic respiratory failure in pediatrics. J Pediatr 1994; 124: 881-888.
85. Griffiths MJ, Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353: 2683-2695.
86. Griffiths MJ, Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353: 2683-2695.
87. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. New Engl J Med 1993; 328: 399-405.
88. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxy radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624.
89. Robbins CG, Davis JM, Merritt TA, Amirkhanian JD, Sahgal N, Morin FC, Horowitz S. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. Am J Physiol 1995; 269: L545-50.
90. Hallman M. Molecular interactions between nitric oxide and lung surfactant. Biol Neonate 1997; 71: 44-8.
91. Ballard PL, Merrill JD, Truog WE, Godinez RI, Godinez MH, McDevitt TM, Ning Y, Golombek SG, Parton LA, Luan X, Cnaan A, Ballard RA. Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics 2007; 120: 346-53.
92. McMahon TJ, Doctor A. Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc Am Thorac Soc 2006; 3:153-60.
93. Sonveaux P, Lobysheva II, Feron O, McMahon TJ. Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) 2007; 22: 97-112.
94. Top AP, Ince C, Schouwenberg PH, Tibboel D. Inhaled nitric oxide improves systemic microcirculation in infants with hypoxemic respiratory failure. Pediatr Crit Care Med 2012;13: 1-4.
95. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
96. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in fullterm and nearly full-term infants with hypoxic respiratory failure. New Engl J Med 1997; 336: 597-604.
97. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342: 469-74.
98. Day RW, Lynch JM, White KS, Ward RM. Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics 1996; 98: 698-705.
99. Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336: 605-10.
100. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr. 2000;136:611-617.
101. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics 1997; 99: 838-45.
102. Karamanoukian H, Glick P, Zayek M, et al. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios. Pediatrics. 1994;94:715.
103. Frostell CG, Lonnqvist PA, Sonesson SE, et al. Near fatal pulmonary hypertension after surgical repair of congenital diaphragmatic hernia. Anesthesia. 1993;48:679-683.
104. Al-Hathlol K, Elmahdy H, Nawaz S, Ali I, Al-Saif S, Tawakol H, Tawil K. Perioperative course of pulmonary hypertension in infants with congenital diaphragmatic hernia: impact on outcome following successful repair. J Pediatr Surg. 2011;46:625-9.
105. Mohseni-Bod H, Bohn D. Pulmonary hypertension in congenital diaphragmatic hernia. Semin Pediatr Surg 2007; 16:126-33.
106. Shiyanagi S, Okazaki T, Shoji H, Shimizu T, Tanaka T, Takeda S, Kawashima K, Lane GJ, Yamataka A. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone. Pediatr Surg Int 2008; 24: 1101-4.
107. Inamura N, Kubota A, Nakajima T, Kayatani F, Okuyama H, Oue T, Kawahara H. A proposal of new therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia. J Pediatr Surg 2005; 40: 1315-9.
108. North AJ, Moya FR, Mysore MR, Thomas VL, Wells LB, Wu LC, Shaul PW. Pulmonary endothelial nitric oxide synthase gene expression is decreased in a rat model of congenital diaphragmatic hernia. Am J Respir Cell Mol Biol 1995; 13: 676-82.
109. Karamanoukian HL, Peay T, Love JE, Abdel-Rahman E, Dandonna P, Azizkhan RG, Glick PL. Decreased pulmonary nitric oxide synthase activity in the rat model of congenital diaphragmatic hernia. J Pediatr Surg 1996; 31: 1016-9.
110. Siebert H, Haas JE, Beckwith JB. Left ventricular hypoplasia in congenital diaphragmatic hernia. J Pediatr Surg 1984;19:567-571.
111. Schwart SM, Vermilion RP, Hirschl RB: Evaluation of left ventricular mass in children with left-sided congenital diaphragmatic hernia. J Pediatr 1994 ;125:447-451.
112. Barefield ES, Karle VA, Phillips JB, Carlo WA. Inhaled nitric oxide in term infants with hypoxemic respiratory failure. J Pediatr 1996; 129: 279-86.
113. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998; 101: 325-34.
114. Macrae DJ, Field D, Mercier JC, Møller J, Stiris T, Biban P, Cornick P, Goldman A, Göthberg S, Gustafsson LE, Hammer J, Lönnqvist PA, Sanchez-Luna M, Sedin G, Subhedar N. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004; 30: 372-80.
115. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009; 56: 579-600.
116. Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124: 302-8.
117. The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomized controlled trial. Lancet. 1999;354: 1066-1071
118. Cornfield DN, Maynard RC, deRegnier RA, Guiang SF, Barbato JE, Milla CE. Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics 1999; 104: 1089-94.
119. Tworetzky W, Bristow J, Moore P, Brook MM, Segal MR, Brasch RC, Hawgood S, Fineman JR. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001;357:118-20.
120. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999; 104: 231-6.
121. Kinsella JP, Griebel J, Schmidt JM, Abman SH. Use of inhaled nitric oxide during interhospital transport of newborns with hypoxemic respiratory failure. Pediatrics 2002; 109: 158-61.
122. Clark RH, Huckaby JL, Kueser TJ, Walker MW, Southgate WM, Perez JA, Roy BJ, Keszler M. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol 2003; 23: 300-3.
123. Cheung PY, Salas E, Etches PC, Phillipos E, Schulz R, Radomski MW. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates. Lancet 1998; 351: 1181-1182.
124. Hogman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and nitric oxide inhalation. Lancet 1993; 341: 1664-1665.
125. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxy radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624.
126. Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, Martin RJ, Truog WE, Ballard PL, Zadell A, Wadlinger SR, Coburn CE, Ballard RA. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. J Pediatr 2010; 156: 556-61.e1
127. Maderuelo Rodríguez E, Sanz López E, Franco Fernández ML, Bernardo Atienza B, Sánchez Luna M. Rescue treatment with inhaled nitric oxide in preterm newborns with respiratory failure. An Pediatr (Barc).2005;62:68-71.
128. Dewhurst C, Ibrahim H, Göthberg S, Jónsson B, Subhedar N. Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry. Acta Paediatr 2010; 99: 854-60.
129. Lin YJ, Markham NE, Balasubramaniam V, Tang JR, Maxey A, Kinsella JP, Abman SH. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. 2005;58:22-9.
130. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287:L344-L351.
131. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641-3.
132. Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G, Grover TR, Abman SH Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2005;289:L529-35.
133. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2003;283:L555-62.
134. McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, Yoder BA, Kerecman JD, Albertine KH, Winter VT, Coalson JJ, Crapo JD, Grubb PH, Shaul PW. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol. 2005;288:L450-9.
135. Qian L, Liu H, Yu W, Wang X, Sun Z, Wang W, Zhu L, Sun B Effects of positive end-expiratory pressure, inhaled nitric oxide and surfactant on expression of proinflammatory cytokines and growth factors in preterm piglet lungs. Pediatr Res. 2008;64:17-23.
136. Hu X, Guo C, Sun. Inhaled nitric oxide attenuates hyperoxic and inflammatory injury without alteration of phosphatidylcholine synthesis in rat lungs. Pulm Pharmacol Ther.2007;20:75-84.
137. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch DH. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011; 127: 363-9.
138. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-13.
139. Bishop NB, Stankiewicz P, Steinhorn RH. Alveolar Capillary Dysplasia. Am J Respir Crit Care Med 2011.
140. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91: 283-90.
141. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002; 359: 1781-2.
142. Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcón-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol 2010; 27: 225-30.
143. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117: 1077-83.
144. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994;266: 536-543.
145. Martell M, Blasina F, Silvera F, Tellechea S, Godoy C, Vaamonde L, Benenatti L, Olivera W Intratracheal sildenafil in the newborn with pulmonary hypertension. Pediatrics 2007;119:215-216.
146. Ryhammer PK, Shekerdemian LS, Penny DJ, Ravn HB Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res 2006;59:762-766.
147. Shekerdemian LS, Ravn HB, Penny DJ Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004;55:413-418.
148. Shekerdemian LS, Ravn HB, Penny DJ Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-1102.
149. Hemnes AR, Champion HC. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Rev Cardiovasc Ther 2006; 4: 293-300.
150. Fesler P, Pagnamenta A, Rondelet B, Kerbaul F, Naeije R. Effects of sildenafil on hypoxic pulmonary vascular function in dogs. J Appl Physiol 2006; 101: 1085-90.
151. Nieminen T, Kööbi T, Tammela TL, Kähönen M. Hypotensive potential of sildenafil and tamsulosin during orthostasis. Clin Drug Investig 2006; 26: 667-71.
152. Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology 2006; 68: 47-60.
153. Tessler R, Wu S, Fiori R, Macgowan CK, Belik J. Sildenafil acutely reverses the hypoxic pulmonary vasoconstriction response of the newborn pig. Pediatr Res 2008; 64:251-5.
154. Cornet AD, Hofstra JJ, Swart EL, Girbes AR, Juffermans NP. Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med 2010; 36:758-64.
155. Herrea J, Castillo R, Concha E, Soliz A. Oralsildenafil treatment as an alternative to inhaled NO therapy for persistent pulmonary hypertension of the newborn. E-PAS2006:59:3724.3.
156. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, Wessel DL. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009; 155: 841-847.
157. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006; 174: 1042-7.
158. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307-10.
159. Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 2004; 88: 306-7.
160. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154: 379-84, 384.e1-2.
161. Rashid N, Morin FC, Swartz DD, Ryan RM, Wynn KA, Wang H, Lakshminrusimha S, Kumar VH. Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. Pediatr Res 2006; 60: 624-9.
162. Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar VH, Russell JA, Steinhorn RH. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2009; 10: 106-12.
163. Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89: 1-5.
164. Bassler D, KreutzerK, McNamara P,KirpalaniH. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD007802. DOI: 10.1002/14651858.CD007802.pub2.
165. UK Collaborative ECMO Trail Group: UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348:75-82.
166. Walsh MC, Stork EK. Persistent pulmonary hypertension of the newborn. Rational therapy based on pathophysiology. Clin Perinatol 2001; 28: 609-27.
167. Bartlett RH, Gazzaniga AB, Jefferies R, et al: Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs 22:80-88, 1976.
168. Extracorporeal Life Support Registry. International Summary Report January 2011.
169. Hintz SR, Suttner DM, Sheehan AM, Rhine WD, Van Meurs KP. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 2000; 106: 1339-43.
170. Kössel H, Bauer K, Kewitz G, Karaca S, Versmold H. Do we need new indications for ECMO in neonates pretreated with high-frequency ventilation and/or inhaled nitric oxide? Intensive Care Med 2000; 26: 1489-95.
171. Clark RH, The Near-Term Respiratory Failure Research Group The Epidemiology of Respiratory Failure in Neonates Born at an Estimated Gestational Age of 34 Weeks or More Journal of Perinatology 2005; 25:251-257.
172. Kays D, Langham M, Ledbetter D, et al. Detrimental effects of standard medical therapy in congenital diaphragmatic hernia. Ann Surg. 1999;230:340-348.
173. Bohn D. Congenital diaphragmatic hernia. Am J Respir Crit Care Med. 2002;166:911-915.
174. Downard CD, Jaksic T, Garza JJ, et al. Analysis of an improved survival rate for congenital diaphragmatic hernia.J Pediatr Surg. 2003;38:729-732.
175. Stolar CJ: What do survivors of congenital diaphragmatic hernia look like when they grow up? Semin Pediatr Surg 5:275-279, 1996.
176. McGahren ED, Mallik K, Rodgers BM: Neurological outcome is diminished in survivors of congenital diaphragmatic hernia requiring extracorporeal membrane oxygenation J Pediatr Surg 32:1216-1220, 1997.